GlaxoSmithKline in Second Round Talks with PE Funds

GlaxoSmithKline is in second round talks with a group of private equity funds and strategic buyers interested in buying its non-core over-the-counter products, Reuters reported, citing the Financial Times. The sale could fetch as much as 1.5 billion pounds ($2.4 billion). Bain Capital, Blackstone and German pharmaceutical group Boehringer Ingelheim are reported to be in the bidding process.

DealsNorth AmericaUSBriefs